Ten-gene biomarker panel: a new hope for ovarian cancer?

Dong-Joo Cheon, Sandra Orsulic
2014 Biomarkers in Medicine  
The recent publication of a 10-gene biomarker panel generates new hope for the prognostication and personalization of therapy in ovarian cancer. Expression of the 10 biomarker genes (AEBP1, COL11A1, COL5A1, COL6A2, LOX, POSTN, SNAI2, THBS2, TIMP3, VCAN) in primary ovarian tumors correlates with metastasis, recurrence and poor survival. Importantly, the utility of the 10-gene panel extends beyond biomarkers since most of these genes play key roles in tumor progression and some have already been
more » ... hown to be effective therapeutic targets in pre-clinical models. Current challenge in ovarian cancer management Survival rates for advanced stage ovarian cancer have not changed significantly over the past 40 years and ovarian cancer remains the most lethal gynecologic cancer in women. The most common type of ovarian cancer, and the one that accounts for the majority of deaths from ovarian cancer, is serous papillary carcinoma. Approximately 20% of patients with this ovarian cancer subtype are intrinsically resistant to chemotherapy or develop chemoresistant disease within one year from initial treatment. Currently, ovarian cancer surveillance and subsequent therapies are implemented on a "watch-and-wait" basis because there is no diagnostic tool that identifies patients who have a high likelihood of recurrence. A reliable method to identify these poor prognosis patients would facilitate their inclusion into clinical trials or personalized treatment strategies at an earlier point. One successful example of such approach is the development and validation of the Oncotype DX ® and Mammaprint ® assays for breast cancer [1, 2], which have become the standard of care for individualized treatment decision-making in breast cancer. Unlike in breast cancer, a fully-validated and clinically-*
doi:10.2217/bmm.14.16 pmid:24796616 pmcid:PMC4330556 fatcat:h5dw6phhgrhs7jjcpdoauqqsh4